Add BrightSurf on Google Email

European Society of Cardiology


What's age got to do with it?

New research from the European Society of Cardiology shows that physiological health, as measured by exercise stress testing performance, is a better predictor of survival than chronological age. This finding suggests that individuals who are physically fit may live longer than those who are not.

SourceEuropean Society of Cardiology·JournalEuropean Journal of Preventive Cardiology·DateFeb 14, 2019

Too much or too little sleep linked to increased risk of cardiovascular disease and death

A recent study published in the European Heart Journal found that both excessive and insufficient sleep are linked to an increased risk of cardiovascular disease and death. The research analyzed data from 116,632 adults aged between 35 and 70 years, revealing a significant association between sleep duration and cardiovascular health.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateDec 4, 2018

Best of ESC Congress 2018

At ESC Congress 2018, a record 156 countries were represented, with over 4,500 abstracts presented in 500 expert sessions. Key clinical trials included MARINER, CAMELLIA-TIMI 61, and ASCEND, which may impact practice and guideline updates. The congress also featured new guidelines for hypertension care.

New treatment can halve hospital stays for some patients with heart infection

A new treatment has been found to significantly reduce hospital stays for patients with heart infections by halving the duration of intravenous antibiotic treatment. The POET trial showed that giving patients oral antibiotics after at least ten days of intravenous treatment was as effective and safe as continued intravenous treatment, ...

SourceEuropean Society of Cardiology·JournalNew England Journal of Medicine·DateAug 28, 2018

Percutaneously reducing secondary mitral regurgitation in heart failure appears futile

Researchers found that reducing secondary mitral regurgitation in heart failure patients did not improve survival or symptoms, suggesting the procedure is futile. Despite successful procedure completion, there was no significant difference in primary endpoint outcomes between intervention and medical treatment groups.

SourceEuropean Society of Cardiology·JournalNew England Journal of Medicine·DateAug 27, 2018

Antithrombin drug not effective in heart failure with sinus rhythm and coronary disease

The COMMANDER HF trial found that rivaroxaban did not significantly reduce the risk of death, myocardial infarction, or stroke in patients with recent worsening of chronic heart failure and coronary artery disease. Rivaroxaban was associated with a lower rate of nonfatal stroke, but a higher risk of major bleeding compared to placebo.

SourceEuropean Society of Cardiology·JournalNew England Journal of Medicine·DateAug 27, 2018